Theranexus SA - Asset Resilience Ratio

Latest as of December 2025: 66.61%

Theranexus SA (ALTHX) has an Asset Resilience Ratio of 66.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Theranexus SA PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€7.02 Million
≈ $8.21 Million USD Cash + Short-term Investments

Total Assets

€10.54 Million
≈ $12.33 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Theranexus SA's Asset Resilience Ratio has changed over time. See Theranexus SA (ALTHX) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Theranexus SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALTHX stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €7.02 Million 66.61%
Total Liquid Assets €7.02 Million 66.61%

Asset Resilience Insights

  • Very High Liquidity: Theranexus SA maintains exceptional liquid asset reserves at 66.61% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Theranexus SA Industry Peers by Asset Resilience Ratio

Compare Theranexus SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Theranexus SA (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Theranexus SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 66.61% €7.02 Million
≈ $8.21 Million
€10.54 Million
≈ $12.33 Million
+53.12pp
2024-12-31 13.49% €504.56K
≈ $589.88K
€3.74 Million
≈ $4.37 Million
-69.47pp
2021-12-31 82.97% €14.01 Million
≈ $16.38 Million
€16.89 Million
≈ $19.75 Million
+54.34pp
2020-12-31 28.63% €5.00 Million
≈ $5.85 Million
€17.47 Million
≈ $20.42 Million
-49.79pp
2019-12-31 78.42% €12.05 Million
≈ $14.09 Million
€15.37 Million
≈ $17.97 Million
-6.65pp
2018-12-31 85.07% €16.03 Million
≈ $18.75 Million
€18.85 Million
≈ $22.04 Million
+72.96pp
2016-12-31 12.11% €348.87K
≈ $407.86K
€2.88 Million
≈ $3.37 Million
-39.08pp
2015-12-31 51.19% €1.40 Million
≈ $1.63 Million
€2.73 Million
≈ $3.19 Million
--
pp = percentage points

About Theranexus SA

PA:ALTHX France Biotechnology
Market Cap
$58.92 Million
€50.40 Million EUR
Market Cap Rank
#22310 Global
#350 in France
Share Price
€3.49
Change (1 day)
-6.18%
52-Week Range
€0.76 - €4.37
All Time High
€22.70
About

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more